Trials / Unknown
UnknownNCT05329025
A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer
A Study of the Safety and Efficacy of QL1706 in Combination With Chemotherapy in First-Line Treatment of Patients With Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of QL1706 when given in combination with bevacizumab, paclitaxel or pemetrexed, and carboplatin in patients with Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer (NSCLC). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 | QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit. |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2024-01-01
- Completion
- 2024-01-01
- First posted
- 2022-04-14
- Last updated
- 2023-11-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05329025. Inclusion in this directory is not an endorsement.